{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:49:51Z","timestamp":1791614991008,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.acvd.2016.08.002","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T09:01:00Z","timestamp":1482397260000},"page":"51-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Cardiovascular remodeling and the peripheral serotonergic system"],"prefix":"10.1016","volume":"110","author":[{"given":"Estelle","family":"Ayme-Dietrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Aubertin-Kirch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-8603","authenticated-orcid":false,"given":"Luc","family":"Maroteaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Monassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2016.08.002_bib0315","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/clc.4950260706","article-title":"The Bezold-Jarisch reflex in acute inferior myocardial infarction: clinical and sympathovagal spectral correlates","volume":"26","author":"Chiladakis","year":"2003","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0320","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.tips.2008.06.009","article-title":"5-hydroxytryptamine and cardiovascular regulation","volume":"29","author":"Ramage","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.acvd.2016.08.002_bib0325","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.RES.45.5.629","article-title":"Serotonin metabolism in the normal and failing hamster heart","volume":"45","author":"Sole","year":"1979","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2016.08.002_bib0330","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/01.CIR.99.3.411","article-title":"Monoamine- and histamine-synthesizing enzymes and neurotransmitters within neurons of adult human cardiac ganglia","volume":"99","author":"Singh","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2016.08.002_bib0335","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0735-1097(02)02158-7","article-title":"The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts","volume":"40","author":"Shimizu","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0340","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.neuropharm.2008.07.010","article-title":"Effects of serotonin in failing cardiac ventricle: signalling mechanisms and potential therapeutic implications","volume":"55","author":"Levy","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.acvd.2016.08.002_bib0345","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.cardiores.2004.11.017","article-title":"Appearance of a ventricular 5-HT4 receptor-mediated inotropic response to serotonin in heart failure","volume":"65","author":"Qvigstad","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2016.08.002_bib0350","doi-asserted-by":"crossref","first-page":"e45489","DOI":"10.1371\/journal.pone.0045489","article-title":"The cardiac ventricular 5-HT4 receptor is functional in late foetal development and is reactivated in heart failure","volume":"7","author":"Brattelid","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.acvd.2016.08.002_bib0355","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.bjp.0706501","article-title":"Fading of 5-HT4 receptor-mediated inotropic responses to 5-hydroxytryptamine is caused by phosphodiesterase activity in porcine atrium","volume":"147","author":"Kaumann","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0360","doi-asserted-by":"crossref","first-page":"H2367","DOI":"10.1152\/ajpheart.01375.2006","article-title":"Serotonin increases L-type Ca2+ current and SR Ca2+ content through 5-HT4 receptors in failing rat ventricular cardiomyocytes","volume":"293","author":"Birkeland","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0365","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bjp.0706966","article-title":"Effects of treatment with a 5-HT4 receptor antagonist in heart failure","volume":"150","author":"Birkeland","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0370","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s002100000299","article-title":"5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle","volume":"363","author":"Bach","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0375","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.yjmcc.2005.04.009","article-title":"Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes","volume":"39","author":"Castro","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0380","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/01.RES.0000176970.22603.8d","article-title":"Dual serotonergic regulation of ventricular contractile force through 5-HT2A and 5-HT4 receptors induced in the acute failing heart","volume":"97","author":"Qvigstad","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2016.08.002_bib0385","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1097\/HJH.0000000000000695","article-title":"Contribution of serotonin to cardiac remodeling associated with hypertensive diastolic ventricular dysfunction in rats","volume":"33","author":"Ayme-Dietrich","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.acvd.2016.08.002_bib0390","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00702-013-1011-3","article-title":"Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice","volume":"120","author":"Lairez","year":"2013","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.acvd.2016.08.002_bib0395","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.yjmcc.2011.07.019","article-title":"Serotonin 5-HT2A receptor-mediated hypertrophy is negatively regulated by caveolin-3 in cardiomyoblasts and neonatal cardiomyocytes","volume":"52","author":"Mialet-Perez","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0400","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bbrc.2009.12.001","article-title":"Essential role of TRPC1 channels in cardiomyoblasts hypertrophy mediated by 5-HT2A serotonin receptors","volume":"391","author":"Vindis","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.acvd.2016.08.002_bib0405","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.yjmcc.2008.12.019","article-title":"Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT2A receptors","volume":"46","author":"Yabanoglu","year":"2009","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0410","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ajh.23855","article-title":"Platelet activation and arterial peripheral serotonin turnover in cardiac remodeling associated to aortic stenosis","volume":"90","author":"Rouzaud-Laborde","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0415","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCRESAHA.108.180976","article-title":"Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy","volume":"104","author":"Jaffre","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2016.08.002_bib0420","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/01.CIR.0000139856.20505.57","article-title":"Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts","volume":"110","author":"Jaffre","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2016.08.002_bib0425","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/HYPERTENSIONAHA.107.105551","article-title":"Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice","volume":"52","author":"Monassier","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.acvd.2016.08.002_bib0430","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1096\/fj.02-1122fje","article-title":"Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT2B receptor signaling","volume":"17","author":"Nebigil","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.acvd.2016.08.002_bib0435","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cardiores.2006.08.003","article-title":"Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-kappaB in cardiomyocytes","volume":"72","author":"Liang","year":"2006","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2016.08.002_bib0440","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/HJH.0000000000000159","article-title":"Old spontaneously hypertensive rats gather together typical features of human chronic left-ventricular dysfunction with preserved ejection fraction","volume":"32","author":"Marzak","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.acvd.2016.08.002_bib0445","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0399-8320(05)88172-2","article-title":"[Carcinoid heart disease: an underestimated complication of endocrine digestive tumors]","volume":"29","author":"Goichot","year":"2005","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0450","doi-asserted-by":"crossref","first-page":"E72","DOI":"10.1111\/j.1540-8175.2012.01781.x","article-title":"Live\/real time three-dimensional transthoracic echocardiographic assessment of the involvement of cardiac valves and chambers in carcinoid disease","volume":"29","author":"Dumaswala","year":"2012","journal-title":"Echocardiography"},{"key":"10.1016\/j.acvd.2016.08.002_bib0455","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/eurheartj\/ehr089","article-title":"Quadruple valve replacement for valve destruction in carcinoid heart disease","volume":"32","author":"McAlindon","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2016.08.002_bib0460","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","article-title":"Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients","volume":"87","author":"Pellikka","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2016.08.002_bib0465","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.77.2.264","article-title":"Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2016.08.002_bib0470","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.2014-2247","article-title":"Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial","volume":"100","author":"Pavel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.acvd.2016.08.002_bib0475","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2016.08.002_bib0480","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1472-8206.2012.01027.x","article-title":"Mitral bioprosthesis hypertrophic scaring and native aortic valve fibrosis during benfluorex therapy","volume":"26","author":"Ayme-Dietrich","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0485","doi-asserted-by":"crossref","first-page":"H1940","DOI":"10.1152\/ajpheart.01177.2008","article-title":"Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study","volume":"296","author":"Droogmans","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0490","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/S0002-9440(10)64497-5","article-title":"Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells","volume":"161","author":"Xu","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0495","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","article-title":"3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro","volume":"63","author":"Setola","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0500","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.yjmcc.2012.08.012","article-title":"5-HT(2B) antagonism arrests non-canonical TGF-beta1-induced valvular myofibroblast differentiation","volume":"53","author":"Hutcheson","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0505","first-page":"626","article-title":"Organ culture as a tool to identify early mechanisms of serotonergic valve disease","volume":"19","author":"Barzilla","year":"2010","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.acvd.2016.08.002_bib0510","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.athoracsur.2011.03.084","article-title":"Aortic valve cyclic stretch causes increased remodeling activity and enhanced serotonin receptor responsiveness","volume":"92","author":"Balachandran","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.acvd.2016.08.002_bib0515","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/cvr\/cvs238","article-title":"Developmental basis for filamin-A-associated myxomatous mitral valve disease","volume":"96","author":"Sauls","year":"2012","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2016.08.002_bib0520","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.pharmthera.2010.08.004","article-title":"Contribution of gene-modified mice and rats to our understanding of the cardiovascular pharmacology of serotonin","volume":"128","author":"Monassier","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.acvd.2016.08.002_bib0525","series-title":"S\u00e9rotonine\u00a0: aspects biologiques et cliniques","first-page":"85","article-title":"Chapitre 5. Facteur de r\u00e9gulation fonctionnelle et structurale dans l\u2019appareil cardiovasculaire","author":"Monassier","year":"2012"},{"key":"10.1016\/j.acvd.2016.08.002_bib0530","first-page":"1219","article-title":"Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts","volume":"37","author":"Fujita","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0535","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2011.10.042","article-title":"Role of serotonin in angiogenesis: induction of angiogenesis by sarpogrelate via endothelial 5-HT1B\/Akt\/eNOS pathway in diabetic mice","volume":"220","author":"Iwabayashi","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2016.08.002_bib0540","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1248\/bpb.b12-00401","article-title":"Mechanism of inverse agonist action of sarpogrelate at the constitutively active mutant of human 5-HT2A receptor revealed by molecular modeling","volume":"35","author":"Hossain","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.acvd.2016.08.002_bib0545","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1254\/jphs.FP0060610","article-title":"Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor","volume":"102","author":"Muntasir","year":"2006","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.acvd.2016.08.002_bib0550","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2176\/nmc.53.291","article-title":"Sarpogrelate dilates cerebral arteries in the absence of exogenous serotonin","volume":"53","author":"Kawamura","year":"2013","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"10.1016\/j.acvd.2016.08.002_bib0555","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jvs.2009.05.065","article-title":"Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts","volume":"50","author":"Kodama","year":"2009","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.acvd.2016.08.002_bib0560","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2014.02.043","article-title":"The role of endothelium-derived hyperpolarizing factor and cyclooxygenase pathways in the inhibitory serotonergic response to the pressor effect elicited by sympathetic stimulation in chronic sarpogrelate treated rats","volume":"731","author":"Garcia-Pedraza","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0565","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0021-9150(03)00054-6","article-title":"Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism","volume":"168","author":"Hayashi","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2016.08.002_bib0570","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/S0003-4975(01)02599-1","article-title":"Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency","volume":"71","author":"Sharma","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.acvd.2016.08.002_bib0575","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0021-9150(01)00505-6","article-title":"Serotonin potentiates angiotensin II--induced vascular smooth muscle cell proliferation","volume":"159","author":"Watanabe","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2016.08.002_bib0580","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5761\/atcs.oa.12.02061","article-title":"Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans","volume":"19","author":"Ren","year":"2013","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"10.1016\/j.acvd.2016.08.002_bib0585","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00380-013-0334-1","article-title":"Effect of sarpogrelate treatment on the prognosis after endovascular therapy for critical limb ischemia","volume":"29","author":"Takahara","year":"2014","journal-title":"Heart Vessels"},{"key":"10.1016\/j.acvd.2016.08.002_bib0590","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.4103\/0366-6999.158285","article-title":"Prospective randomized study of sarpogrelate versus clopidogrel-based dual antiplatelet therapies in patients undergoing femoropopliteal arterial endovascular interventions: preliminary results","volume":"128","author":"Chen","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.acvd.2016.08.002_bib0595","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/FJC.0b013e3180325af3","article-title":"Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease","volume":"49","author":"Miyazaki","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0600","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005344-200402000-00015","article-title":"Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model","volume":"43","author":"Takishita","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0605","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1253\/circj.70.1451","article-title":"Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease","volume":"70","author":"Kokubu","year":"2006","journal-title":"Circ J"},{"key":"10.1016\/j.acvd.2016.08.002_bib0610","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijcard.2009.09.539","article-title":"Sarpogrelate protects against high glucose-induced endothelial dysfunction and oxidative stress","volume":"147","author":"Sun","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2016.08.002_bib0615","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1254\/jphs.12009FP","article-title":"Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes","volume":"119","author":"Yamada","year":"2012","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.acvd.2016.08.002_bib0620","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pharmthera.2005.12.004","article-title":"5-hydroxytryptamine receptors in the human cardiovascular system","volume":"111","author":"Kaumann","year":"2006","journal-title":"Pharmacol Ther"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213616301656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213616301656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:43:54Z","timestamp":1761745434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213616301656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1875213616301656"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2016.08.002","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular remodeling and the peripheral serotonergic system","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2016.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}